India may be on the verge of making weight-loss drugs similar to Ozempic more affordable. As patents for these drugs expire, cheaper generics are anticipated, with some reports suggesting the cost could be as low as $3 per month to produce. The potential impact of this development on the global obesity fight and the cost of these drugs for patients, including those in the US, is being closely watched.